Clinical trial NCT00345189 (phase 1, status: completed)
Conditions: tumors, lymphoma
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cnf2024
SMILES: COC1=C(C)C=NC(CN2C=NC3=C(Cl)NC(=N)N=C23)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumor which has failed standard
             therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which
             effective therapy is not available

          -  At least 18 years of age

          -  Hematology: Absolute neutrophil count (ANC) > 1500 cells/mm3, platelet count > 100,000
             cells/mm3 and hemoglobin >= 9 gm/L

          -  Hepatic: Bilirubin < 1.5 X upper limit of normal (ULN); alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases
             or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
             < 5.0 X ULN.

          -  Renal: Serum creatinine levels < 2.0 mg/dL or creatinine clearance > 60 mL/min

          -  Coagulation: international normalized ratio (INR) < 1.5 times normal

          -  Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels

          -  Normal electrocardiogram (ECG) with QTc <= 450 msec for men and <= 470 msec for women

          -  Estimated life expectancy of at least 3 months as determined by the Investigator

          -  Eastern Cooperative Oncology Group (ECOG) performance status <= 2

          -  Male and female patients of childbearing potential must practice effective
             double-barrier contraception during the study and continue contraception for 3 months
             after their last dose of study drug. Male patients must agree to not have intercourse
             with pregnant or nursing women during the study and for 3 months after their last dose
             of study drug, unless using double-barrier contraception. The only exceptions to
             double-barrier contraception are: Patient or partner is surgically sterile,female
             patient is postmenopausal for at least 1 year before screening or patient abstains
             from sexual intercourse, at the discretion of the Investigator

        Exclusion Criteria:

          -  Pregnant or nursing women, women of child-bearing age not using reliable means of
             contraception.

          -  Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less
             from chemotherapy-induced toxic effect, except alopecia, is required.

          -  Participation in any investigational drug study within 28 days prior to CNF2024
             administration

          -  Active infection requiring intravenous antibiotic treatment

          -  Patients with second malignancy requiring active treatment (except hormonal therapy)

          -  Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes,
             hypertension, coronary artery disease, congestive heart failure)

          -  Active symptomatic fungal, bacterial and/or viral infection including active HIV or
             viral (A, B or C) hepatitis

          -  Problems with swallowing or malabsorption

          -  Chronic diarrhea (excess of 2-3 stools/day above normal frequency)

          -  Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or
             hemorrhagic coloproctitis

          -  Major surgery of the stomach or small intestine

          -  Adrenal dysfunction > Grade 2

          -  Patients with diabetes (your doctor will discuss if you are eligible for this study)